NovaBay Pharmaceuticals, a biopharmaceutical company focusing on the commercialization and development of its non-antibiotic anti-infective products, said on Thursday that it has signed a nationwide distribution agreement with AmerisourceBergen.
Under the agreement, AmerisourceBergen will carry and distribute NovaBay’s Avenova -- a prescription lid- and lash-hygiene product for the management of debilitating eye conditions such as blepharitis, Meibomian gland dysfunction and associated dry eye -- to independent and retail chain pharmacies across the U.S.
“Our agreement with AmerisourceBergen represents yet another major achievement in our commercial strategy,” Dr. Ron Najafi, chairman and CEO of NovaBay, said. “Patients who can benefit from Avenova are now assured that the product will be available through almost every pharmacy in America.”
The new agreement means Avenova now will be available in the majority of the country’s 67,000 pharmacies and in thousands of ophthalmologist and optometrist offices across the nation.
“While it’s early in the commercial launch, we are encouraged by the market's initial acceptance of Avenova,” Glenn Moro, vice president of sales and marketing at NovaBay, said. “We now have sales representatives in major markets across the country calling on top-prescribing optometrists and ophthalmologists. Our agreement with AmerisourceBergen will further increase the effectiveness of our sales team by making Avenova accessible to virtually every patient.”